# Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

> **NCT00920855** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cephalon** · enrollment: 40 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bendamustine
- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00920855
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920855, "Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00920855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*